Myriad Genetics Inc (MYGN)

Debt-to-capital ratio

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Long-term debt US$ in thousands
Total stockholders’ equity US$ in thousands 701,100 731,700 740,500 760,000 783,200 683,400 735,200 835,200 885,800 916,600 947,400 950,100 967,800 968,600 902,500 875,200 879,900 909,300 918,200 967,200
Debt-to-capital ratio 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

December 31, 2024 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $701,100K)
= 0.00

The debt-to-capital ratio for Myriad Genetics Inc has consistently been at 0.00% for the past several quarters, indicating that the company has not utilized debt as a significant part of its capital structure. A debt-to-capital ratio of 0.00% suggests that the company's capital is primarily funded by equity rather than debt. This could indicate a lower financial risk for the company as it does not have significant debt obligations to repay. However, it's important to note that a low or zero debt-to-capital ratio may also limit the company's financial flexibility in terms of leveraging debt for potential growth opportunities.


Peer comparison

Dec 31, 2024